- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06270706
Une étude de phase 1 sur le PLN-101095 chez des adultes atteints de tumeurs solides avancées ou métastatiques
Une étude de phase 1a/1b multicentrique ouverte sur l'augmentation/l'expansion de la dose pour évaluer l'innocuité, la tolérabilité, la pharmacocinétique et les preuves préliminaires de l'activité antitumorale du PLN-101095 en monothérapie et en association avec le pembrolizumab chez des participants adultes atteints de tumeurs solides avancées ou métastatiques Qui ont une progression de la maladie pendant le traitement par pembrolizumab
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory [primary resistance]) or relapsed [secondary resistance]) after at least 3 months from the start of treatment with pembrolizumab.
The study will consist of 2 main parts:
- Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration
- Part 2: Dose-expansion cohorts using Simon's 2-stage design
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Pliant Therapeutics Medical Monitor
- Numéro de téléphone: clintrials@pliantrx.com
- E-mail: clintrials@pliantrx.com
Lieux d'étude
-
-
Barcelona
-
Barcelona, Barcelona, Espagne, 08023
- Recrutement
- Hospital Universitari Quirónsalud (NEXT Barcelona)
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Barcelona, Barcelona, Espagne, 08023
- Recrutement
- START Barcelona - Hospital HM Nou Delfos
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Barcelona, Barcelona, Espagne, 08035
- Recrutement
- Hospital Universitari Vall d'Hebron - VHIO
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
La Rioja
-
Logroño, La Rioja, Espagne, 26006
- Recrutement
- START Center for Cancer Research - La Rioja
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Madrid
-
Madrid, Madrid, Espagne, 28040
- Recrutement
- START Madrid - Hospital Universitario Fundación Jiménez Díaz
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Madrid, Madrid, Espagne, 28050
- Recrutement
- START Madrid - Centro Integral Oncológico Clara Campal
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Pozuelo de Alarcón
-
Madrid, Pozuelo de Alarcón, Espagne, 28223
- Recrutement
- University Hospital Quironsalud Madrid (NEXT Madrid)
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06511
- Complété
- Yale University
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20007
- Recrutement
- Georgetown University Medical Center
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Recrutement
- Winship Cancer Institute of Emory University
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Michigan
-
Grand Rapids, Michigan, États-Unis, 49546
- Recrutement
- South Texas Accelerated Research Therapeutics (START)
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63110
- Recrutement
- Washington University Medicine
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
New Jersey
-
East Brunswick, New Jersey, États-Unis, 08816
- Recrutement
- START New Jersey
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
New Brunswick, New Jersey, États-Unis, 08901
- Recrutement
- Rutgers Cancer Institute of New Jersey
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
New York
-
Lake Success, New York, États-Unis, 11042
- Recrutement
- START New York Long Island LLC
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
North Carolina
-
Wilson, North Carolina, États-Unis, 27893
- Recrutement
- Carolina Cancer Research Center
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
South Dakota
-
Sioux Falls, South Dakota, États-Unis, 57105
- Recrutement
- Avera Medical Group
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- Tennessee Oncology
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Texas
-
Austin, Texas, États-Unis, 78758
- Recrutement
- NEXT Austin
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Fort Worth, Texas, États-Unis, 76104
- Recrutement
- START Center for Clinical Research
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Houston, Texas, États-Unis, 77030
- Recrutement
- University of Texas MD Anderson Cancer Center
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Houston, Texas, États-Unis, 77054
- Recrutement
- NEXT Houston
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
San Antonio, Texas, États-Unis, 78229
- Recrutement
- UT Health San Antonio's Mays Cancer Center
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Utah
-
West Valley City, Utah, États-Unis, 84119
- Recrutement
- START Mountain Region
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- Recrutement
- Inova Schar Cancer Institute
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Fairfax, Virginia, États-Unis, 22031
- Recrutement
- NEXT Virginia
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Washington
-
Edmonds, Washington, États-Unis, 98026
- Recrutement
- Swedish Cancer Institute Medical Oncology
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Has histologically or cytologically confirmed advanced or metastatic solid tumor
- Have received ≥12 weeks of continuous anti-PD-1 or anti-PD-L1 treatment administered as monotherapy or in combination with other anticancer therapies
- Have demonstrated documented prior clinical benefit, defined as CR or PR at any time during treatment, or SD lasting ≥6 months (Part 2 only)
- Must have subsequently developed radiographic disease progression while receiving anti-PD-1 or anti-PD-L1 treatment or within ≤12 weeks after the last dose of such treatment
- At least 1 measurable lesion, as defined by RECIST v1.1
- Estimated survival of ≥3 months
- Have adequate bone marrow and organ function.
- A female participant is eligible to participate if she is not pregnant, not breastfeeding
Exclusion Criteria:
- Any immune-related medical conditions that would put participants at greater risk when receiving pembrolizumab
- Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
- Has received prior radiotherapy within 2 weeks for palliative bone-directed therapy and 4 weeks for all other radiotherapy
- Has undergone major surgery within 4 weeks prior to the first dose of study treatment or has not adequately recovered from surgery or related complications
- Has a diagnosis of immunodeficiency or use of systemic steroids >10 mg/day
- Has an active autoimmune disease that has required systemic treatment in the past 2 years
- Has known active CNS metastases (brain and/or leptomeningeal metastases)
- Has significant cardiac disease
- Has an active infection requiring systemic therapy (including uncontrolled HIV, Hepatitis B and C)
- Has received a live or live-attenuated vaccine within 30 days or a non-live vaccine within 7 days prior to the first dose of PLN-101095
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part 1 Dose Escalation - 250 mg BID
Cohort 1 PLN-101095 250 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Expérimental: Part 1 Dose Escalation - 500 mg BID
PLN-101095 500 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Expérimental: Part 1 Dose Escalation - 1000 mg BID
PLN-101095 1000 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Expérimental: Part 1 Dose Escalation - 1000 mg TID
PLN-101095 1000 mg TID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Expérimental: Part 1 Dose Escalation - 2000 mg BID
PLN-101095 2000 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Expérimental: Part 2 Dose Expansion - NSCLC
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Non-small cell lung cancer (NSCLC) |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Expérimental: Part 2 Dose Expansion - ccRCC
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Clear cell renal cell carcinoma (ccRCC) |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Expérimental: Part 2 Dose Expansion - TMB-high solid tumors
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Tumor mutational burden (TMB)-high solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
Délai: First dose to 35 days
|
Number of participants with a Dose Limiting Toxicity (DLT) defined as toxicities that meet predefined severity criteria, assess as having a suspected relationship to study drug, unrelated to disease, inter-current illness, or concomitant medications. |
First dose to 35 days
|
|
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
Délai: Day 1 until 16 weeks after end of study treatment regimen
|
Proportion of participants with treatment-emergent adverse events and serious adverse events. |
Day 1 until 16 weeks after end of study treatment regimen
|
|
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Délai: First dose to disease progression or death from any cause, whichever occurs first.
|
Proportion of participants achieving confirmed iPR or iCR per iRECIST Version 1.1. |
First dose to disease progression or death from any cause, whichever occurs first.
|
|
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Délai: First dose to disease progression or death from any cause, whichever occurs first.
|
Proportion of participants who maintain disease control (iCR, iPR or iSD) per iRECIST Version 1.1. |
First dose to disease progression or death from any cause, whichever occurs first.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Délai: Day 14, 0 to up to 12 hours
|
Maximum drug concentration (Cmax) |
Day 14, 0 to up to 12 hours
|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Délai: Day 14, 0 to up to 12 hours
|
Time to Cmax (Tmax) |
Day 14, 0 to up to 12 hours
|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Délai: Day 14, 0 to up to 12 hours
|
Area under the concentration-time curve (AUC0-τ) |
Day 14, 0 to up to 12 hours
|
|
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Délai: First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first
|
Duration of response (DOR) for objective responders |
First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first
|
|
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Délai: First dose to progression or death from any cause, whichever occurs first
|
Time on treatment (TOT) for objective responders |
First dose to progression or death from any cause, whichever occurs first
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Pliant Therapeutics Medical Monitor, Pliant Therapeutics, Inc.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
- Carcinome urothélial
- Immunothérapie
- Pembrolizumab
- Mélanome
- Cancer colorectal
- Cancer de l'endomètre
- Cancer du poumon non à petites cellules (NSCLC)
- Cholangiocarcinome
- Cancer des tumeurs solides avancées
- Vésicule biliaire
- Carcinome ovarien
- Cancer du sein triple négatif (TNBC)
- Carcinome anal
- Carcinome à cellules rénales transparentes (CCRCC)
- Carcinome des voies biliaires (CVB)
- Carcinome épidermoïde de la tête et du cou (CÉTC)
- Tumeurs à forte charge mutationnelle tumorale (TMB)
- Tumeurs à faible TMB
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- Maladies du système endocrinien
- Processus pathologiques
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs
- Maladies urogénitales masculines
- Maladies rénales
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladies intestinales
- Maladies des voies respiratoires
- Tumeurs par type histologique
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies du système digestif
- Maladies gastro-intestinales
- Tumeurs intestinales
- Maladies rectales
- Maladies utérines
- Maladies génitales, femme
- Maladies pulmonaires
- Tumeurs des glandes endocrines
- Tumeurs, glandulaires et épithéliales
- Adénocarcinome
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Maladies du côlon
- Processus néoplasiques
- Tumeurs pulmonaires
- Maladies ovariennes
- Maladies annexielles
- Tumeurs génitales, femme
- Troubles gonadiques
- Maladies de la peau
- Maladies du sein
- Tumeurs urologiques
- Carcinome
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Tumeurs rénales
- Carcinome bronchique
- Tumeurs bronchiques
- Tumeurs utérines
- Tumeurs neuroendocrines
- Nevi et mélanomes
- Tumeurs cutanées
- Tumeurs mammaires
- Maladies de l'anus
- Tumeurs rectales
- Conditions pathologiques, signes et symptômes
- Maladies de la peau et du tissu conjonctif
- Tumeurs colorectales
- Tumeurs ovariennes
- Métastase néoplasmique
- Carcinome à cellules rénales
- Carcinome pulmonaire non à petites cellules
- Cholangiocarcinome
- Mélanome
- Tumeurs mammaires triples négatives
- Tumeurs de l'endomètre
- Carcinome à cellules transitionnelles
- Tumeurs de l'anus
- pembrolizumab
Autres numéros d'identification d'étude
- PLN-101095-ONC-101
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .